Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 2
1958 2
1964 1
1965 2
1966 8
1967 4
1968 31
1969 20
1970 8
1971 5
1972 9
1973 12
1974 15
1975 34
1976 18
1977 28
1978 23
1979 20
1980 23
1981 22
1982 29
1983 39
1984 41
1985 24
1986 17
1987 40
1988 20
1989 37
1990 51
1991 45
1992 47
1993 56
1994 79
1995 77
1996 79
1997 83
1998 99
1999 93
2000 116
2001 133
2002 133
2003 178
2004 177
2005 199
2006 211
2007 251
2008 247
2009 237
2010 254
2011 245
2012 245
2013 287
2014 275
2015 299
2016 302
2017 262
2018 300
2019 300
2020 351
2021 294
2022 280
2023 272
2024 89

Text availability

Article attribute

Article type

Publication date

Search Results

6,439 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Schizophrenia 10"
Page 1
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Huhn M, et al. Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11. Lancet. 2019. PMID: 31303314 Free PMC article.
We aimed to compare and rank antipsychotics by quantifying information from randomised controlled trials. METHODS: We did a network meta-analysis of placebo-controlled and head-to-head randomised controlled trials and compared 32 antipsychotics. ...Two authors indep …
We aimed to compare and rank antipsychotics by quantifying information from randomised controlled trials. METHODS: We did a network m …
Cannabis use and risk of schizophrenia: a Mendelian randomization study.
Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, Smith DJ, Pell JP, Sattar N, Paré G, Holmes MV. Vaucher J, et al. Mol Psychiatry. 2018 May;23(5):1287-1292. doi: 10.1038/mp.2016.252. Epub 2017 Jan 24. Mol Psychiatry. 2018. PMID: 28115737 Free PMC article.
Cannabis use is observationally associated with an increased risk of schizophrenia, but whether the relationship is causal is not known. Using a genetic approach, we took 10 independent genetic variants previously identified to associate with cannabis use in 32 330 …
Cannabis use is observationally associated with an increased risk of schizophrenia, but whether the relationship is causal is not kno …
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Leucht S, et al. Lancet. 2013 Sep 14;382(9896):951-62. doi: 10.1016/S0140-6736(13)60733-3. Epub 2013 Jun 27. Lancet. 2013. PMID: 23810019 Review.
BACKGROUND: The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. ...METHODS: We did a Bayesian-framework …
BACKGROUND: The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and con …
Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.
Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Khandaker GM, et al. Lancet Psychiatry. 2015 Mar;2(3):258-270. doi: 10.1016/S2215-0366(14)00122-9. Epub 2015 Feb 25. Lancet Psychiatry. 2015. PMID: 26359903 Free PMC article. Review.
In this Review, we describe some of the important areas of research regarding innate and adaptive immune response in schizophrenia and related psychotic disorders that, we think, will be of interest to psychiatric clinicians and researchers. We discuss potential mechanisms …
In this Review, we describe some of the important areas of research regarding innate and adaptive immune response in schizophrenia an …
Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.
Bighelli I, Rodolico A, García-Mieres H, Pitschel-Walz G, Hansen WP, Schneider-Thoma J, Siafis S, Wu H, Wang D, Salanti G, Furukawa TA, Barbui C, Leucht S. Bighelli I, et al. Lancet Psychiatry. 2021 Nov;8(11):969-980. doi: 10.1016/S2215-0366(21)00243-1. Epub 2021 Oct 12. Lancet Psychiatry. 2021. PMID: 34653393 Free article.
We aimed to evaluate the efficacy, acceptability, and tolerability of psychosocial and psychological interventions for relapse prevention in schizophrenia. METHODS: To conduct this systematic review and network meta-analysis we searched for published and unpublished ran …
We aimed to evaluate the efficacy, acceptability, and tolerability of psychosocial and psychological interventions for relapse prevention in …
Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.
Rosenbrock H, Desch M, Wunderlich G. Rosenbrock H, et al. Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1557-1566. doi: 10.1007/s00406-023-01576-z. Epub 2023 Mar 27. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 36971864 Free PMC article. Review.
Cognitive impairment associated with schizophrenia (CIAS) is a major burden for patients and negatively impacts many aspects of a patient's life. ...A Phase II study has demonstrated that iclepertin is safe and well tolerated in patients with schizophrenia and impro …
Cognitive impairment associated with schizophrenia (CIAS) is a major burden for patients and negatively impacts many aspects of a pat …
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.
Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. Lobo MC, et al. Neurosci Biobehav Rev. 2022 Jan;132:324-361. doi: 10.1016/j.neubiorev.2021.11.032. Epub 2021 Nov 24. Neurosci Biobehav Rev. 2022. PMID: 34838528 Review.
This narrative review compares the pharmacology, clinical trial data and tolerability of novel medications to representative antipsychotics. ...These medications largely have favourable cardiometabolic side-effect profiles. Overall, the novel pharmacology, clinic …
This narrative review compares the pharmacology, clinical trial data and tolerability of novel medications to representative a …
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD. Pillinger T, et al. Lancet Psychiatry. 2020 Jan;7(1):64-77. doi: 10.1016/S2215-0366(19)30416-X. Epub 2019 Dec 17. Lancet Psychiatry. 2020. PMID: 31860457 Free PMC article.
METHODS: We searched MEDLINE, EMBASE, and PsycINFO from inception until June 30, 2019. We included blinded, randomised controlled trials comparing 18 antipsychotics and placebo in acute treatment of schizophrenia. ...However, the choice of antipsychotic should be ma …
METHODS: We searched MEDLINE, EMBASE, and PsycINFO from inception until June 30, 2019. We included blinded, randomised controlled tri …
Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data.
Efthimiou O, Taipale H, Radua J, Schneider-Thoma J, Pinzón-Espinosa J, Ortuño M, Vinkers CH, Mittendorfer-Rutz E, Cardoner N, Tanskanen A, Fusar-Poli P, Cipriani A, Vieta E, Leucht S, Tiihonen J, Luykx JJ. Efthimiou O, et al. Lancet Psychiatry. 2024 Feb;11(2):102-111. doi: 10.1016/S2215-0366(23)00366-8. Epub 2024 Jan 9. Lancet Psychiatry. 2024. PMID: 38215784
BACKGROUND: There is debate about the generalisability of results from randomised clinical trials (RCTs) to real-world settings. Studying outcomes of treatments for schizophrenia can shed light on this issue and inform treatment guidelines. ...The target popu …
BACKGROUND: There is debate about the generalisability of results from randomised clinical trials (RCTs) to real-world setting …
Maintenance treatment with antipsychotic drugs for schizophrenia.
Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM, Leucht S. Ceraso A, et al. Cochrane Database Syst Rev. 2020 Aug 11;8(8):CD008016. doi: 10.1002/14651858.CD008016.pub3. Cochrane Database Syst Rev. 2020. PMID: 32840872 Free PMC article.
OBJECTIVES: To review the effects of maintaining antipsychotic drugs for people with schizophrenia compared to withdrawing these agents. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials including the registries of clin …
OBJECTIVES: To review the effects of maintaining antipsychotic drugs for people with schizophrenia compared to withdrawing these agen …
6,439 results